MEDS - TRxADE HEALTH, Inc.
Chart Events
Commodity Channel Index
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 0.2735 |
| Open | 0.2780 |
| Bid | 0.2701 x 1200 |
| Ask | 0.2929 x 1000 |
| Day's Range | 0.2763 - 0.2780 |
| 52 Week Range | 0.2510 - 1.7900 |
| Volume | |
| Avg. Volume | 142,501 |
| Market Cap | 2.821M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3100 |
| Earnings Date | Jul 24, 2023 - Jul 28, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.90 |
Fair Value
Related Research
Insider MonkeyTRxADE HEALTH, Inc. (NASDAQ:MEDS) Q1 2023 Earnings Call Transcript
TRxADE HEALTH, Inc. (NASDAQ:MEDS) Q1 2023 Earnings Call Transcript May 15, 2023 TRxADE HEALTH, Inc. misses on earnings expectations. Reported EPS is $-0.12 EPS, expectations were $-0.04. Operator: Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to TRxADE HEALTH’s Quarter One 2023 Earnings Conference Call. During today’s presentation, all parties will be […]
- Thomson Reuters StreetEvents
Q1 2023 TRxADE Health Inc Earnings Call
Q1 2023 TRxADE Health Inc Earnings Call
ZacksTRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates
TRxADE (MEDS) delivered earnings and revenue surprises of -50% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ACCESSWIRETRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results
TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the quarter ended March 31, 2023.
ZacksSimilar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates
Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 2.94% and 39.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- ACCESSWIRE
TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m. Eastern Time
TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 15, 2023. Please note that this is a revised date from the original reporting date of May 8, 2023.
ZacksTRxADE (MEDS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
TRxADE (MEDS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- ACCESSWIRE
TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m. Eastern Time
TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for the first quarter 2023, after market close on May 8, 2023.
Insider MonkeyTRxADE HEALTH, Inc. (NASDAQ:MEDS) Q4 2022 Earnings Call Transcript
TRxADE HEALTH, Inc. (NASDAQ:MEDS) Q4 2022 Earnings Call Transcript March 27, 2023 Operator: Good afternoon, ladies and gentlemen. Thank you for standing by. Welcome to TRxADE HEALTH’s 2022 Annual Earnings Conference Call. The earnings press release accompanying this conference call was issued at the close of the market today. The company’s annual report, which includes […]
ZacksTRxADE (MEDS) Reports Q4 Loss, Tops Revenue Estimates
TRxADE (MEDS) delivered earnings and revenue surprises of -66.67% and 8.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- ACCESSWIRE
TRxADE HEALTH Reports 16% Revenue Growth and Year End 2022 Financial Results
TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the year ended December 31, 2022.
- ACCESSWIRE
TRxADE HEALTH, INC. to Report Q4 and Year-End 2022 Financial Results on Monday, March 27th at 5:30 p.m. Eastern Time
TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for fourth quarter and year-end 2022, after market close on March 27, 2023.
ZacksAll You Need to Know About TRxADE (MEDS) Rating Upgrade to Strong Buy
TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
- ACCESSWIRE
Bonum Health(TM), LLC (a TRxADE HEALTH Company) Reaffirms its Commitment to Independent Pharmacies and Group Purchasing Organizations (GPOs) with its Novel Telemedicine Services Model
TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE" or the "Company") an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary, has signed a preferred telemedicine services agreement with an independent group purchasing organization (GPO) which will provide deep discounts to access Bonum Health's service platform for 100+ pharmacies and their patient's in the northeastern
ZacksTRxADE (MEDS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
TRxADE (MEDS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
ZacksAll You Need to Know About TRxADE (MEDS) Rating Upgrade to Buy
TRxADE (MEDS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Simply Wall St.TRxADE HEALTH Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
TRxADE HEALTH ( NASDAQ:MEDS ) Third Quarter 2022 Results Key Financial Results Revenue: US$2.40m (down 5.9% from 3Q...
InvestorPlace7 Meme Stocks Smart Investors Shouldn’t Touch With a 10-Foot Pole
Meme stocks represented one of the most remarkable developments in the equities space during much of the new normal. However, by 2022, this sector received a very rude awakening. To be fair, this space enjoys backing from powerful Internet communities, making a shorting proposition wildly risky. So, that’s not what I’m going to talk about. Instead, I will gently encourage you to consider limiting your exposure to these meme stocks to avoid. Frankly, meme stocks have become far too risky. Althoug
ZacksTRxADE (MEDS) Reports Q3 Loss, Lags Revenue Estimates
TRxADE (MEDS) delivered earnings and revenue surprises of 50% and 27.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireTRxADE HEALTH Reports Third Quarter Gross Margin of 58% and Q3 2022 Financial Results
Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform TAMPA, FL, Nov. 07, 2022 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS) (“TRxADE” or the “Company”), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the 2022 third quarter (Q3) ended September 30, 2022. Third Quarter 2022 and Subseque
- GlobeNewswire
Bonum Health™, LLC (a TRxADE HEALTH Company) Strikes Strategic Business-to-Business (B2B) Telemedicine Services Agreement with Insurance Brokerage Firm(s) for Small-to-Medium Business (SMB) Employer Groups
TAMPA, FL, Oct. 25, 2022 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS)(“TRxADE” or the “Company”) an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary, has struck a strategic services distribution agreement with multiple insurance brokerage firms to offer access to telemedicine services for small to medium employer groups. The Company, which offers nationwide telemedicine services in all 50 states
- ACCESSWIRE
TRxADE HEALTH, INC. to Report Third Quarter 2022 Financial Results on Monday, November 7th at 5:00 p.m. Eastern Time
TRxADE HEALTH INC. (NASDAQ:MEDS), is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., will release financial results for third quarter 2022, after market close on November 7, 2022.
- ACCESSWIRE
TRxADE Health Announces Pricing of $1.8 Million Registered Direct Offering
TRxADE HEALTH, INC. (NASDAQ:MEDS) ("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.8 million of its common stock (or pre-funded warrants in lieu thereof)
- GlobeNewswire
TRxADE HEALTH, INC. Taps Advisory Board Member and Leading Pharmaceutical Industry Expert, Mr. Jeff Newell, For its Board of Directors
TAMPA, FL, Oct. 03, 2022 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ: MEDS)("TRxADE" or the "Company"), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., announced today the appointment of Mr. Jeff Newell to the Company's Board of Directors. Prior to his appointment to the Board of Directors, Mr. Newell served on the Company’s Advisory Board. Mr. Newell will serve as
- ACCESSWIRE
Wakefern Food Corp. and Bonum Health(TM), LLC (a TRxADE HEALTH Company) Ink a Telemedicine Services Deal
TRxADE HEALTH, INC. (NASDAQ:MEDS)("TRxADE" or the "Company") an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary, has signed a Telemedicine Services Distribution Deal with Wakefern Food Corp., to deploy telemedicine services throughout ShopRite pharmacy-led locations in New Jersey, New York, Pennsylvania, Connecticut, and Maryland.